The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Investigating the role of cemiplimab in non-small cell lung cancer
Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, comments on the efficacy of cemiplimab in treating non-small cell lung cancer (NSCLC), highlighting its strong role in both histological subtypes, including squamous cell carcinoma. Whilst there have been no trials directly comparing cemiplimab to other checkpoint inhibitors in this setting, it has a promising future due to is efficacy, regardless of histology. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Unfortunately, there are no just cross-over trials available just to compare all the PD-L1 inhibitors to each other. Just we can talk about our data that the cemiplimab data where we are presenting now strongly shows that cemiplimab has its really important role in the treatment of non-small cell lung cancer regardless of histology. And it’s important that we have demonstrated that it’s also an important part in the treatment of the squamous cell, non-small cell lung cancer, because we’ve shown 22 months of overall survival in squamous histology...
Unfortunately, there are no just cross-over trials available just to compare all the PD-L1 inhibitors to each other. Just we can talk about our data that the cemiplimab data where we are presenting now strongly shows that cemiplimab has its really important role in the treatment of non-small cell lung cancer regardless of histology. And it’s important that we have demonstrated that it’s also an important part in the treatment of the squamous cell, non-small cell lung cancer, because we’ve shown 22 months of overall survival in squamous histology.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
